URGN

URGN

USD

UroGen Pharma Ltd. Ordinary Shares

$9.870-0.140 (-1.399%)

即時價格

Healthcare
生物科技
美國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$10.010

最高

$10.050

最低

$9.720

交易量

0.06M

公司基本面

市值

466.0M

行業

生物科技

國家

United States

交易統計

平均交易量

0.43M

交易所

NGM

貨幣

USD

52週範圍

最低 $8.94當前 $9.870最高 $20.7

AI分析報告

最後更新: 2025年4月17日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

[URGN: UroGen Pharma Ltd. Ordinary Shares]: Positive News & Price Hints - What's Next?

Stock Symbol: URGN Generate Date: 2025-04-17 05:30:13

Let's take a look at what's happening with UroGen Pharma (URGN). We've got some fresh news, price history, and even what the AI is predicting. Let's break it down without the jargon.

Recent News Buzz: Good Vibes Only?

The latest news for URGN is definitely leaning positive. Think of it like this:

  • Good News #1: Wall Street Likes What They See. Scotiabank, a big financial player, just started covering UroGen and gave them a "Sector Outperform" rating. Basically, they're saying they expect URGN to do better than other companies in the same area (biotech). They even set a price target of $23. That's a good sign that experts are seeing potential.
  • Good News #2: Science is Progressing. UroGen is presenting data at a big urology conference. This is about their work on cancer treatments. Specifically, they're talking about positive results from studies on their drugs for bladder and upper tract urothelial cancers. Good data at conferences often gets investors excited because it means the company's drugs might be working well and moving closer to helping patients (and making money).

In short, the news is positive because experts are giving them thumbs up and their research seems to be going well. No negative news in sight here.

Price Check: Where's the Stock Been & Where Might It Go?

Looking back at the last month or so, URGN's stock price has been a bit of a rollercoaster, but with an interesting recent twist.

  • The Bumpy Ride: If you look at the price chart, you'll see it was kind of drifting downwards from late January into early March. Then, it started to climb back up in March. April has been a bit up and down again, but it seems to be trying to find its footing.
  • Recent Days - A Little Lift? Over the last few trading days, it looks like the price has been inching upwards. It closed yesterday around $10.74.
  • AI's Crystal Ball: Now, the AI prediction is saying it expects the price to go up a bit each day for the next few days. Not a huge jump, but a steady climb. It's predicting around a 1% increase today, then a bit more tomorrow and the day after.

So, the stock has been through some ups and downs, but recently it's showing signs of potentially moving upwards, and the AI seems to agree.

Outlook & Strategy Ideas: What Could This Mean for You?

Putting it all together, here's a possible way to look at URGN right now:

  • Near-Term Lean: Given the positive news sentiment, the recent slight upward price movement, and the AI's prediction of further gains, the situation seems to be leaning towards a potentially bullish short-term outlook. It might be a time where buyers are starting to get interested.
  • Thinking About Entry? If you were considering getting into URGN, a possible entry point could be around the current price level (around $10.70 - $10.80). This is roughly where the stock is trading now, and it's also close to some of the potential entry points suggested by the recommendation data ($10.68, $10.80). Of course, prices can always change.
  • Where to Take Profit or Cut Losses? If things go well and the stock rises as predicted, a potential area to think about taking some profit could be around $11.68. That's the "take-profit" level mentioned in the recommendation data. On the flip side, to manage risk, a potential stop-loss level could be around $9.69. This is below recent lows and the suggested stop-loss in the data. A stop-loss is just a point where you decide to sell if the price drops to limit potential losses.

Important Note: These are just potential ideas based on the data we have right now. The market is unpredictable, and things can change quickly.

Company Context - Quick Background

Just a quick reminder about UroGen Pharma itself: They're in the biotech business, specifically focused on cancers of the urinary system. So, positive news about their drug development is really important for this company. They are still a smaller company (market cap around $478 million) in the healthcare sector.

In a nutshell: URGN has some positive news backing it up, the price is showing some signs of life, and AI predictions are cautiously optimistic. It might be an interesting stock to watch, but always remember to do your own research and understand the risks.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

相關新聞

BusinessWire

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that

查看更多
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
BusinessWire

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd.

查看更多
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
BusinessWire

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

Data Presented at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that

查看更多
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
BusinessWire

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium Presentation at the American Urological Association

查看更多
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
BusinessWire

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation UGN-301 formulated in a reverse thermal gel allowed sustained exposure in the

查看更多
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
Analyst Upgrades

Goldman Sachs Maintains Neutral on UroGen Pharma, Lowers Price Target to $16

Goldman Sachs analyst Paul Choi maintains UroGen Pharma with a Neutral and lowers the price target from $22 to $16.

Analyst Upgrades

Scotiabank Initiates Coverage On UroGen Pharma with Sector Outperform Rating, Announces Price Target of $23

Scotiabank initiates coverage on UroGen Pharma with a Sector Outperform rating and announces Price Target of $23.

AI預測Beta

AI推薦

看漲

更新於: 2025年4月28日 上午01:50

看跌中立看漲

62.7% 信心度

風險與交易

風險級別3/5
中等風險
適合
價值
交易指南

入場點

$9.89

獲利了結

$10.73

止損

$8.87

關鍵因素

DMI 顯示熊市趨勢 (ADX:16.8, +DI:7.5, -DI:11.3),建議謹慎
當前價格非常接近支撐位 ($9.89),表明強勁的買入機會
交易量是平均值 (5,723) 的 7.7 倍,表明極強的買入壓力
MACD -0.0238 在信號線 -0.0118 下方,表示看跌交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。